The recent clinical trials, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) [5] and Canagliflozin Cardiovascular Assessment Study (CANVAS) [6], which investigated the use of sodium glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes, have shown that these inhibitors have additional cardiovascular protective properties. The gene discussed is SLC5A2; the disease is diabetes mellitus.